MAP2K7 and melanoma: Due to the different time of drug approval of those anti‐PD1 blockades, BRAF and MEK inhibitors in China, we have treated Stage III melanoma in real‐world clinical practice, either with adjuvant immunotherapy using Pembrolizumab or other anti‐PD1 inhibitor, or with adjuvant Vemurafenib monotherapy or Dabrafenib plus Trametinib combination in the past.